Brown Brothers Harriman & Co. Acquires Shares of 813 Korro Bio, Inc. (NASDAQ:KRRO)

Brown Brothers Harriman & Co. bought a new stake in shares of Korro Bio, Inc. (NASDAQ:KRRO) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 813 shares of the company’s stock, valued at approximately $28,000.

Several other large investors also recently modified their holdings of the stock. Rhumbline Advisers bought a new position in shares of Korro Bio in the second quarter worth $279,000. Bank of New York Mellon Corp bought a new position in shares of Korro Bio in the second quarter worth $649,000. Monashee Investment Management LLC bought a new position in shares of Korro Bio in the fourth quarter worth $4,352,000. 72 Investment Holdings LLC bought a new position in shares of Korro Bio in the fourth quarter worth $13,269,000. Finally, Eventide Asset Management LLC bought a new position in shares of Korro Bio in the fourth quarter worth $26,185,000. 13.18% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently commented on KRRO shares. HC Wainwright restated a “buy” rating and issued a $100.00 price target on shares of Korro Bio in a research report on Tuesday. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $95.00 price objective on shares of Korro Bio in a research note on Thursday. Finally, William Blair started coverage on Korro Bio in a research note on Wednesday, August 14th. They issued an “outperform” rating and a $180.00 price objective on the stock. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $135.00.

Korro Bio Stock Up 4.8 %

NASDAQ:KRRO opened at $38.50 on Friday. The stock’s 50-day simple moving average is $43.73 and its 200 day simple moving average is $51.31. Korro Bio, Inc. has a twelve month low of $9.15 and a twelve month high of $97.91.

Korro Bio (NASDAQ:KRRO) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($2.43) EPS for the quarter, missing analysts’ consensus estimates of ($2.39) by ($0.04). As a group, sell-side analysts predict that Korro Bio, Inc. will post -10.29 EPS for the current year.

Korro Bio Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).